Nov 11, 2024, New York, NY — Cayuga Biotech, a company that develops drugs that harness the body’s innate ability to stop bleeding, will be presenting data for its first generation, first-in-class, polyphosphate (polyP)-based therapy at the 19th International Symposium on Blood Substitutes in National Harbor, Maryland from November 14-18, 2024.
Presentation Details:
Title: A synthetic short-chain polyphosphate (polyP) complexed with silica nanoparticle (SNP, polyP-SNP), corrects coagulopathy under hemodilute, hypothermic, or acidotic conditions as assessed by in vitro coagulation assays
Session Date: Sunday, November 17, 2024
Presentation Time: 10:15 AM – 12:15 PM
About Hemorrhage
Nearly 2 million people globally per year die of hemorrhage, the majority of which is preventable. The top causes of preventable death by hemorrhage are non-compressible hemorrhage sites (such as internal bleeding and penetrating injury) and delays in hemostatic control neither of which are adequately addressed by today’s current care model. Due to the nature of non-compressible hemorrhage sites, the complexity of clinical intervention is time consuming and delays in treatment often lead to patient death.
About Cayuga Biotech, Inc.
Cayuga is developing novel biomimetic therapies leveraging inorganic polyphosphate, a polymer that modulates the healing response. The company has an optimized polyP-SNP complex in late preclinical development for the treatment of acute major hemorrhage, a discovery-stage novel composition for the treatment of inherited bleeding disorders, as well as a portfolio of early-stage programs focused across the healing continuum. To learn more, please visit www.CayugaBiotech.com.
Contact:
Andrea Ashford-Hicks
Media@cayugabiotech.com